

To NASDAQ OMX Copenhagen

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

14 August 2014

INTERIM REPORT FOR THE PERIOD 1 JANUARY - 30 June 2014 (UNAUDITED)**Second quarter highlight: Continued profitability measured on EBITDA driven by improved margins.**

Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") today announced results for the six months of 2014:

In summary (DKK million)	Q2 2014	Q2 2013	H1 2014	H1 2013	Outlook 2014
Revenue	30.7	33.3	63.2	65.1	~ 135
Gross profit	20.2	21.1	42.3	39.5	
EBITDA	0.1	0.5	1.7	-1.6	~ 5
EBIT	-1.5	-0.7	-1.1	-4.1	
Net profit	-1.2	-1.3	-0.5	-5.7	
Cash flows from operating activities	1.3	-0.2	-1.0	-3.4	
EPS	-0.03	-0.03	-0.01	-0.16	

Financial highlights

- Revenue decreased 3% to DKK 63.2 million (DKK 65.1 million) and was affected negatively by a decrease in OEM sales to Exiqon's licensing partners of 29% to DKK 4.9 million (DKK 6.9 million).
- Research product sales and services (excluding OEM sales) decreased 1% to DKK 49.8 million (DKK 50.5 million) due to unfavorable impact of foreign currency exchange rates (DKK 1 million).
- Gross profit increased 7% to DKK 42.3 million (DKK 39.5 million) due to improved margins.
- Total operating expenses of DKK 43.3 million were at the same level as last year (DKK 43.5 million).
- EBITDA improved 208% to DKK 1.7 million (DKK -1.6 million) including non-cash costs of share-based payment of DKK 1.9 million (DKK 1.5 million).
- Net result improved 91% to DKK -0.5 million (DKK -5.7 million). EPS amounted to DKK -0.01 (DKK -0.16).
- Cash flow from operating activities improved to DKK -1.0 million (DKK -3.4 million).
- Full year financial guidance is maintained for EBITDA around DKK 5 million and revised for expected revenues of approximately DKK 150 million to revenues of approximately DKK 135 million.

Operational highlights

- On 23 April 2014 Exiqon announced the launch of highly potent miRCURY LNA™ microRNA Mimics for functional analysis.
- On 6 May 2014 Exiqon announced the launch of its miRCURY™ Exosome Isolation kits for exosome isolation from various biofluids and cell media.
- On 9 May 2014 Exiqon announced the launch of its XploreRNA™ app for advanced cross-database searches, easy interpretation of data and seamless planning of experiments. XploreRNA™ is the first in a series of new apps from Exiqon for scientists in both academia and industry.

In a comment CEO Lars Kongsbak said: *"I am encouraged by our continued profitability, driven by improved margins following last years' supply chain optimizations, despite soft revenues in the first half year. Towards end of the second quarter we have witnessed an accumulation of large orders, and we expect renewed growth in products and services sales will come from new products once our recent growth initiatives begin to take effect in the second half year."*

Key figures for the Exiqon Group (unaudited)

(DKK'000 except key figures)	1 Apr. - 30 Jun. 2014	1. Apr. - 30 Jun. 2013	1 Jan. - 30 Jun. 2014	1 Jan. - 30 Jun. 2013	1 Jan. - 31 Dec. 2013
Income statement					
Revenue	30,722	33,291	63,193	65,056	123,584
Production costs	-10,505	-12,240	-20,930	-25,580	-48,132
Gross profit	20,217	21,051	42,263	39,476	75,452
Research and development costs	-6,469	-5,599	-13,138	-12,337	-24,253
Sales and marketing costs	-10,510	-11,241	-20,901	-21,404	-41,261
Administrative expenses	-4,765	-4,915	-9,280	-9,808	-18,718
EBITDA *)	62	457	1,708	-1,588	-4,100
Operating profit/(loss) (EBIT)	-1,527	-704	-1,056	-4,073	-8,780
Profit/(loss) for the period	-1,243	-1,278	-450	-5,748	-10,682
Total Comprehensive profit/(loss) for the period	-1,153	-1,464	-404	-5,692	-10,997
Balance sheet					
Assets					
Intangible assets			61,033	60,424	61,139
Property, plant and equipment			13,091	2,789	4,361
Non-current assets			77,519	67,008	69,037
Cash and cash equivalents			23,141	27,605	29,190
Current assets			60,385	61,739	58,973
Total assets			137,904	128,747	128,010
Equity and liabilities					
Equity			77,719	80,102	76,219
Non-current liabilities			19,412	15,000	15,258
Current liabilities			40,773	33,645	36,533
Total liabilities			60,185	48,645	51,791
Total equity and liabilities			137,904	128,747	128,010
Cash flow statement					
Depreciation, amortization and impairment			2,764	2,484	4,670
Cash flows from operating activities			-965	-3,383	3,228
Acquisition of intangible assets and property, plant and equipment			-3,240	-781	-4,638
Cash flows from investing activities			-3,240	-581	-4,438
Cash flows from financing activities			-1,872	13,966	12,992
Cash and cash equivalents at the end of period			23,141	27,605	29,190
Key figures					
Number of shares, average			36,874,082	36,874,082	36,874,082
Basic EPS (DKK)	-0.03	-0.03	-0.01	-0.16	-0.29
Diluted EPS (DKK)	-0.03	-0.03	-0.01	-0.16	-0.29
Gross margin	65.8%	63.2%	66.9%	60.7%	61.1%
Assets/Equity (gearing)			1.77	1.61	1.68
Average number of employees			85	76	80
Market price per share (DKK)			8.2	8.4	8.2
Market capitalisation (DKK million)			302.4	307.9	300.5
Price / net asset value			3.89	3.80	3.94
Net interest bearing debt / Equity			0.11	-0.02	-0.05
Net interest bearing debt / EBITDA			5.17	0.94	0.86
Interest coverage			1.57	-3.13	0.38

Basic and diluted EPS have been calculated in accordance with IAS 33 "Earnings per share". Other ratios have been calculated in accordance with "Recommendations & Financial Ratios 2010" issued by the Danish Society of Financial Analysts, dated June 2010. (*) EBITDA (defined as Earnings Before Special Items, Interest, Tax, Depreciation and Amortization) includes non-cash costs of share-based payment in the first six months of 2014 with tDKK 1,904.

FINANCIAL REVIEW

Reported figures are for the full reporting period. Figures for the comparable reporting period last year are stated in parenthesis. The average USD/DKK exchange rate applied to translate revenue and expenses was DKK 5.44 for the first six months of 2014 (DKK 5.69).

Revenue

Total revenue decreased 3% to DKK 63.2 million (DKK 65.1 million) and was affected negatively by a decrease in OEM sales to licensing partners of 29% to DKK 4.9 million (DKK 6.9 million) and exchange rates (DKK 1 million).

Research product sales and services (excluding OEM sales) decreased 1% to DKK 49.8 million (DKK 50.5 million). In Europe, research product sales and services (excluding OEM sales) of DKK 24.5 million were at the same level as the comparable period last year (DKK 24.6 million). In North America, research product sales and services (excluding OEM sales) decreased 2% to DKK 18.0 million (DKK 18.4 million) as a result of weakened exchange rate to the U.S. dollar applied to translate revenue. Adjusted for this effect of exchange rates, North American sales increased 2% compared to the same period last year. In Rest of World sales of DKK 7.3 million were at the same level as the comparable period last year (DKK 7.4 million). In the second quarter of 2014 research product sales and services (excluding OEM sales) decreased 3% to DKK 24.9 million (DKK 25.8 million) primarily attributable to the effect of exchange rates.

Revenue from services which is characterized by periodic variations decreased to DKK 7.6 million (DKK 8.8 million). In the second quarter of 2014 revenue from services decreased to DKK 3.7 million (DKK 4.1 million).

Royalty and license income, which include third-party royalty payments to Exiqon under existing license agreements and upfront payments from new license agreements, accounted for DKK 3.7 million (DKK 4.9 million). Exiqon realized revenue of DKK 3.6 million (DKK 1.6 million) from consortium grants recognized separately as contract research.

Gross profit and margins

Gross profit increased 7% to DKK 42.3 million (DKK 39.5 million) due to improved margins. Gross margins on product sales and services excluding license income and contract research improved to 62.5% (56.3%). In the second quarter of 2014 gross profit was DKK 20.2 million (DKK 21.1 million) and gross margins on product sales and services excluding license income and contract research improved to 61.4% (57.7%).

Operating costs

Total operating costs, excluding production costs, of DKK 43.3 million were at the same level as the same period last year (DKK 43.5 million).

EBITDA and EBIT

EBITDA improved to DKK 1.7 million (DKK -1.6 million) and EBIT totaled DKK -1.1 million (DKK -4.1 million). In the second quarter of 2014 EBITDA decreased to DKK 0.1 million (DKK 0.5 million) and EBIT totaled DKK -1.5 million (DKK -0.7 million).

Cash flow

Cash flow from operating activities was DKK -1.0 million (DKK -3.4 million) primarily reflective of cash flow from primary activities of DKK -1.7 million and net interest and value gains of DKK 0.8 million.

Summarized first six months' financial numbers compared to full year outlook

In the table below, the company's realized performance for the first six months of 2014 has been summarized and compared to the outlook for the full year; including an adjustment of the realized numbers to the exchange rate (USD/DKK 5.50) used as basis for the full year outlook:

(DKK million)	Realized 2014 (USD/DKK 5.44)	Realized 2014 adjusted to USD/DKK 5.50	Outlook 2014 (USD/DKK 5.50)
Revenue	63.2	63.4	~135
EBITDA	1.7	1.7	~5

OPERATIONAL REVIEW

Exiqon Life Sciences

- On 23 April Exiqon announced the launch of highly potent miRCURY LNA™ microRNA Mimics for functional analysis. The new miRCURY LNA™ microRNA Mimics enable sub-nanomolar potency and allow scientists to conduct high quality dose-response experiments for instance by resembling disease situations.
- On 6 May 2014 Exiqon announced the launch of its miRCURY™ Exosome Isolation kits for exosome isolation from various biofluids and cell media. Over the past few years the body of scientific literature has documented the biological importance of exosomes. Exosomes play a key role in cell to cell communication, cell migration, cell differentiation etc. Exosomes contain protein and RNA and may be a preferred target for identification of new biomarkers. However, the isolation of exosomes is challenged by the lack of reproducibility, lack of specificity and tedious work processes. Exiqon's new miRCURY™ Exosome Isolation Kits address these challenges.

The miRCURY™ Exosome Isolation Kits ensure very high recovery of exosomes in less than two hours and is based on non-toxic reagents. By the use of miRCURY™ Exosome Isolation Kits, exosomes may be isolated from divers sources such as serum, plasma, urine, CSF and cell culture media.

- On 9 May 2014 Exiqon announced the launch of its XploreRNA™ app for advanced cross-database searches, easy interpretation of data and seamless planning of experiments. XploreRNA™ allows scientists engaged in transcription analysis to scroll any transcript, view splice sites, SNPs and to zoom in on specific transcripts of interest in an interactive interface. Major databases including Ensembl, miRBase etc., have been cross-annotated to provide for all-in-one searches. Relevant abstracts and original publications have been integrated through PubMed. Products are automatically customized to address search results and readily ordered.

The body of biological data is growing exponentially which makes it challenging for scientists to stay abreast and benefit from big data. Different annotations of major databases make cross-database searches time consuming and complicate the identification of relevant genetic information. e.g. microRNA-mRNA interactions. XploreRNA™ overcomes all of these challenges.

XploreRNA™ is the first in a series of new apps from Exiqon for scientists in both academia and industry.

Exiqon Diagnostics

- Exiqon cannot control all aspects of its collaborative diagnostic programs. All communicated timelines must therefore be considered approximate. An update on timelines for diagnostic programs is provided below:

- *Colon stage II recurrence*

Exiqon Diagnostics is part of a consortium that develops a colon recurrence test that will help identify stage II colon cancer patients, who may be at a significantly higher risk of recurrence and for whom adjuvant chemotherapy may be warranted.

We had expected data from our qPCR test for identification of stage II colorectal patients at high risk of recurrence to be published during the first half of 2014, and the publication has been submitted and accepted for publication as planned, however, data has not yet been published. We expect data to be publically available during the third quarter. No other time lines are affected.

- *Early detection of colorectal cancer based on a simple blood test*

Exiqon Diagnostics is part of a consortium that develops a blood based test for early signs of colon cancer, Exiqon collaborates with leading specialists in colon cancer which includes 7 Danish hospitals. To identify and validated a blood based biomarker our partners have established a very unique collection of blood samples from 4,800 individuals who also have been inspected by colonoscopy. The work on developing a blood based biomarker will continue during the second half of 2014 and publication was planned for second half of 2014 but may not take place until first half 2015.

FINANCIAL OUTLOOK 2014

In place of the previous expectations of revenue of approximately DKK 150 million and EBITDA around DKK 5 million, Exiqon now expects revenues of approximately DKK 135 million and EBITDA around DKK 5 million in 2014.

The outlook for 2014 is based on an average USD/DKK exchange rate of DKK 5.50.

Exiqon continues to pursue license and partnering opportunities during 2014. No significant one-time costs are included in the outlook for 2014, nor are any expected. Any costs related to new warrant grants are not included in the guidance for 2014.

Directors' and Management's statement on the interim report

The Board of Directors and the Executive Management have today considered and approved the interim report of Exiqon A/S for the period 1 January – 30 June 2014.

The interim report has been prepared in accordance with IAS 34 and additional Danish disclosure requirements for the presentation of financial statements by listed companies. The interim report is unaudited.

We consider the accounting policies to be appropriate, the accounting estimates made to be reasonable and the overall presentation of the interim report to be adequate, so that the interim report, in our opinion, gives a true and fair view of the assets, liabilities, financial position and results of operations and cash flows of the group for the period 1 January – 30 June 2014. We consider the Management's statement to give a true and fair description of the development in the Group's activities and economic situation, the results of operations and the Group's financial position as a whole and a description of the significant risks and uncertainty factors, which the Group faces.

Vedbaek, 14 August 2014

Executive Management

Lars Kongsbak, CEO Hans Henrik Chrois Christensen, CFO

Board of Directors

Thorleif Krarup Erik Walldén Michael Nobel Per Wold-Olsen
Chairman Deputy Chairman

Additional information

Lars Kongsbak, CEO, phone +45 4566 0888 (cell: +45 4090 2101)

Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)

Forward-looking statements

Certain parts of this release contain forward-looking information with respect to the plans, projections and future performance of the company, each of which involves significant uncertainties. The company's actual results may differ materially from the information set forth in these statements. Timelines relating to collaborative diagnostic programs should be considered approximate.

Consolidated statement of comprehensive income (unaudited)

(DKK'000)	Note	1 Apr. - 30 Jun. 2014	1. Apr. - 30 Jun. 2013	1 Jan. - 30 Jun. 2014	1 Jan. - 30 Jun. 2013	1 Jan. - 31 Dec. 2013
Revenue	2,3	30,722	33,291	63,193	65,056	123,584
Production costs		-10,505	-12,240	-20,930	-25,580	-48,132
Gross profit		20,217	21,051	42,263	39,476	75,452
Research and development costs		-6,469	-5,599	-13,138	-12,337	-24,253
Sales and marketing costs		-10,510	-11,241	-20,901	-21,404	-41,261
Administrative expenses		-4,765	-4,915	-9,280	-9,808	-18,718
Operating profit/(loss) (EBIT)		-1,527	-704	-1,056	-4,073	-8,780
Financial income		292	847	652	1,405	5,085
Financial expenses		-929	-1,301	-1,836	-2,815	-7,813
Profit/(loss) before tax		-2,164	-1,158	-2,240	-5,483	-11,508
Tax on profit/(loss) for the period		921	-120	1,790	-265	826
Profit/(loss) for the period		-1,243	-1,278	-450	-5,748	-10,682
Other comprehensive income						
<i>Items that may be reclassified subsequently to profit or loss:</i>						
Exchange adjustments relating to foreign subsidiaries		90	-186	46	56	-315
Total comprehensive income and expenses for the period		-1,153	-1,464	-404	-5,692	-10,997
Earnings per share						
Basic EPS		-0.03	-0.03	-0.01	-0.16	-0.29
Diluted EPS		-0.03	-0.03	-0.01	-0.16	-0.29

Consolidated statement of financial position (unaudited)

(DKK'000)	Note	30 Jun. 2014	30 Jun. 2013	31 Dec. 2013
Goodwill		49,368	49,368	49,368
Acquired patent rights		5,412	6,460	5,936
Acquired software licenses		6,023	4,550	4,187
Intangible assets under construction		230	46	1,648
Intangible assets		61,033	60,424	61,139
Leasehold improvements		668	233	586
Production and laboratory equipment		10,370	1,788	3,163
Fixtures and fittings, tools and equipment		1,933	570	591
Tangible assets under construction		120	198	21
Property, plant and equipment		13,091	2,789	4,361
Deferred tax assets		1,709	2,034	1,876
Deposits		1,686	1,761	1,661
Financial assets		3,395	3,795	3,537
Non-current assets		77,519	67,008	69,037
Inventories		14,195	13,257	12,771
Trade receivables		16,487	17,421	13,197
Other receivables		1,682	738	1,216
Refund from Tax Authorities		3,250	1,256	1,250
Prepayments		1,630	1,462	1,349
Receivables		23,049	20,877	17,012
Cash and cash equivalents		23,141	27,605	29,190
Current assets		60,385	61,739	58,973
Total assets		137,904	128,747	128,010
Share capital		36,874	36,874	36,874
Reserves		40,845	43,228	39,345
Equity		77,719	80,102	76,219
Corporate Bonds		15,000	15,000	15,000
Financial lease liabilities		4,412	0	258
Non-current liabilities		19,412	15,000	15,258
Financial lease liabilities		2,525	1,039	403
Trade payables		10,706	8,509	11,881
Short term bank loan		10,036	10,074	10,013
Other payables		8,452	8,517	7,712
Deferred revenue		9,054	5,506	6,524
Current liabilities		40,773	33,645	36,533
Total liabilities		60,185	48,645	51,791
Total equity and liabilities		137,904	128,747	128,010

Consolidated statement of cash flow (unaudited)

(DKK'000)	1 Jan. – 30 Jun. 2014	1 Jan. – 30 Jun. 2013	1 Jan. – 31 Dec. 2013
Operating profit (EBIT)	-1,056	-4,073	-8,780
Depreciation and amortization	2,764	2,484	4,670
Non-cash adjustments (warrants)	1,904	1,477	2,899
Change in working capital	-5,357	-1,514	6,152
Profit on sale of assets	0	-200	-200
Cash flows from primary activities	-1,745	-1,826	4,741
Net interest and value gains	-1,176	-1,510	-2,716
Current tax	1,956	-47	1,203
Cash flows from operating activities	-965	-3,383	3,228
Acquisition of intangible assets	-1,417	-378	-2,616
Acquisition of property, plant and equipment	-1,823	-403	-2,022
Sale of assets	0	200	200
Cash flows from investing activities	-3,240	-581	-4,438
Repayment of lease debt	-1,872	-1,019	-2,022
Proceeds from corporate bonds	0	15,000	15,000
Repayment of deposit and loans	-23	-11	79
Short term bank loan	23	-4	-65
Cash flows from financing activities	-1,872	13,966	12,992
Change in cash and cash equivalents	-6,077	10,002	11,782
Unrealised currency gain/(loss)	28	110	-85
Cash and cash equivalents at the beginning of the period	29,190	17,493	17,493
Cash and cash equivalents at the end of the period	23,141	27,605	29,190

Consolidated statement of changes in equity (unaudited)

Consolidated	Number of shares No.	Share capital (DKK'000)	Other reserves			Total (DKK'000)
			Reserve for exchange adjustments (DKK'000)	Share- based payment (DKK'000)	Retained profit (DKK'000)	
Equity at 1 January 2014	36,874,082	36,874	-624	16,341	23,628	76,219
Profit/(loss) for the year					-450	-450
Exchange adjustments relating to foreign subsidiaries			46			46
Total comprehensive income		0	46	0	-450	-404
Share-based payment				1,904		1,904
Other transactions	0	0	0	1,904	0	1,904
Equity at 30 June 2014	36,874,082	36,874	-578	18,245	23,178	77,719
Equity at 1 January 2013	36,874,082	36,874	-309	13,442	34,310	84,317
Profit/(loss) for the year					-5,748	-5,748
Exchange adjustments relating to foreign subsidiaries			56			56
Total comprehensive income		0	56	0	-5,748	-5,692
Share-based payment				1,477		1,477
Other transactions	0	0	0	1,477	0	1,477
Equity at 30 June 2013	36,874,082	36,874	-253	14,919	28,562	80,102

Notes to the interim financial statements

Note 1 Accounting policies

The interim report of the Exiqon Group for the period 1 January – 30 June 2014 is presented in accordance with IAS 34 and additional Danish disclosure requirements for the presentation of financial statements by listed companies. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements as of 31 December 2013.

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in preparation of the Group's annual consolidated financial statements for the year that ended 31 December 2013, except for the adoption of the new standards IFRS 10-12 effective as of 1 January 2014. The nature and the impact of the new standards/amendments are described below:

IFRS 10 changes the definition of control such that an investor has control over an investee when a) it has power over the investee, b) it is exposed, or has rights, to variable returns from its involvement with the investee and c) has the ability to use its power to affect its return.

IFRS 11 deals with how a joint arrangement of which two or more parties have joint control should be classified and accounted for.

IFRS 12 is a new disclosure standard and is applicable to entities that have interest in subsidiaries, joint arrangements, associates and/or unconsolidated structured entities.

The implementation of the new and revised Standards and Interpretations have not affected the recognition or measurement.

The Management has not made new significant accounting estimates and assumptions besides the ones listed in the annual report for 2013.

Note 2 Revenue

(DKK'000)	1 Apr. - 30 Jun. 2014	1. Apr. - 30 Jun. 2013	1 Jan. – 30 Jun. 2014	1 Jan. – 30 Jun. 2013	1 Jan. – 31 Dec. 2013
Product sales	23,469	24,781	48,310	49,662	96,633
Services	3,731	4,132	7,577	8,814	15,489
License income	1,354	3,732	3,669	4,947	7,652
Contract research *)	2,168	646	3,637	1,633	3,810
	30,722	33,291	63,193	65,056	123,584

*) third party financing of product development.

Note 3 Segment information

Exiqon's Management has organized the reporting in two reportable operating segments: Exiqon Life Sciences and Exiqon Diagnostics.

Exiqon Life Sciences includes the sale of research products for microRNA analysis and services. Life Sciences product sales and services based on the same products are considered to have similar financial characteristics. For reporting purposes these are considered as one segment.

Exiqon Diagnostics includes research and development of a variety of diagnostic tests not yet ready for sale. Exiqon Diagnostics is presented as a reporting segment in accordance with the quantitative thresholds guidance in IFRS 8.

The Group divides its revenue into three geographies: North America, Europe and Rest of World. The split is based on the registered offices of the customers.

Management monitors the operating results of its business segments separately to decide the resource allocation and performance assessments. Segment performance is monitored on operating results (EBITDA/EBIT) as presented in the table below. Financial items and taxes are managed on a corporate level and not allocated to the operating segments.

30 June 2014

(DKK'000)	Life Sciences	Diagnostics	Other ¹⁾	Consolidated
Revenue:				
External customers	61,632	1,561		63,193
Internal customers	635	0	-635	0
Total revenue	62,267	1,561	-635	63,193
EBITDA	9,788	-8,080		1,708
Operating profit/(loss) (EBIT)	7,402	-8,458		-1,056
Net non-operating cost			-1,184	-1,184
Profit (loss) before tax	7,402	-8,458	-1,184	-2,240
Assets	57,525	53,987	26,392	137,904

1) The item 'Other' includes Group eliminations, adjustments and net non-operating items.

Geography

Revenue of the Exiqon Group is distributed on geographical segments as follows:

(DKK'000)	1 Apr. - 30 Jun. 2014	1. Apr. - 30 Jun. 2013	1 Jan. - 30 Jun. 2014	1 Jan. - 30 Jun. 2013	1 Jan. - 31 Dec. 2013
North America	10,152	12,558	21,631	21,551	42,355
Europe	17,990	17,466	33,821	35,561	66,102
Rest of World	2,580	3,267	7,741	7,944	15,127
	30,722	33,291	63,193	65,056	123,584

-oo0oo-